SYSTEMATIC FORMULATION DEVELOPMENT OF IMMEDIATE RELEASE TABLET DOSAGE FORM USING QUALITY BY DESIGN APPROACH

被引:0
|
作者
Saxena, Namrata [1 ]
Shrivastava, Birendra [1 ]
机构
[1] Mylan Labs Ltd, Jinnaram Mandal, Andhra Pradesh, India
关键词
Model antibacterial drug BCS II; Immediate release tablet; Wet granulation; Quality by Design; statistical design of experiments; Design Space;
D O I
10.13040/IJPSR.0975-8232.4(8).3110-24
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The main goal of this study was to develop a stable formulation of model antibacterial drug as an immediate-release tablet systematically using Quality by Design approach of which design of experiments is an integral part. The model drug was found to be a BCS class II drug official in USP having a plasma half-life of three to four hours. The formulation development work was initiated with wet granulation method and a total of three trials were conducted to determine the critical material attributes of the formulation used as factors for the experimental designs. The binder (Povidone K29/32,), Superdisintegrant (Crosscarmellose Sodium), Lubricant (Stearic acid and magnesium stearate), Pregelatinized Starch 1500 (binder and disintegrant) were determined to be critical for the formulation of the model antibacterial drug. A fractional factorial design (FFD) for four factors at two levels was selected to screen the varied response variable. A total of eight trials were conducted (24-1FFD). The four factors viz. Povidone K29/32 (X1), Crosscarmellose Sodium (X2), lubricant ratio (X3) and Pregelatinised starch 1500 IG: EG (X4) were varied as required by the experimental design and the factor levels were coded. (+1 for high and -1 for low). Disintegration time was taken as response variable. A central composite design (CCD) for two factors at three levels was selected to optimize the varied response variable. A total of thirteen trials were conducted. The two factors viz. PovidoneK29/32 (X1), Crosscarmellose Sodium (X2), were varied as required by the experimental design and the factor levels were coded. (+1 for high, 0 for moderate and -1 for low). Friability (5) and in vitro % drug release in 5 minutes (Q5) were taken as response variables. The formulated tablets were evaluated for various precompression parameters like bulk density, tapped density, Carr's index, Hausner's ratio and post compression parameters like thickness, hardness, weight variation, friability, disintegration test and in vitro drug release studies. From this study, it was concluded that optimized formulation containing Crosscarmellose Sodium (8.16%) and Povidone K29/32 (1.37%) showed satisfactory friability, in vitro % drug release at 5 mins (Q5) and other physical characteristics of immediate release tablets. A design space was created using desired levels of response variables. A composition was selected within design space as optimized formulation and internally validated. Linear correlation plots were drawn for the predicted and observed responses.
引用
收藏
页码:3110 / 3124
页数:15
相关论文
共 50 条
  • [21] Development and Optimization of Stability-Indicating Method of Solifenacin Succinate and its Main Product of Degradation in Tablet Dosage form using the Quality by Design Approach
    Raphael Cyriaco Cabral
    Felipe Rebello Lourenço
    Leandro Augusto Calixto
    Journal of Analytical Chemistry, 2023, 78 : S35 - S45
  • [22] Formulation and stability evaluation of immediate release antioxidant tablet
    Sultana, Abida
    Hassan, Fouzia
    Israr, Fozia
    Hasan, Syed Muhammad Farid
    Haque, Naheed
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 27 (05) : 1393 - 1400
  • [23] Assessment of Formulation Factors on the Release Behaviour of BCS Class II Drug from Tablet Dosage form Using DoE
    Syamala, Urmila Sri
    Kumar, Raman Suresh
    Pushkarajan, Tambi Anuj
    Gowthamarajan, Kuppuswamy
    CURRENT DRUG DELIVERY, 2014, 11 (04) : 511 - 520
  • [24] Quality by Design Based Method Development for Simultaneous Estimation of Montelukast Sodium and Theophylline in Tablet Dosage Form
    Shah, Kunti Abhishek
    Parmar, Vijaykumar Kunvarji
    CURRENT PHARMACEUTICAL ANALYSIS, 2019, 15 (06) : 612 - 623
  • [25] FORMULATION DEVELOPMENT OF MICROSPONGE BASED DELAYED RELEASE DOSAGE FORM OF LANSOPRAZOLE
    Tadwee, Imran
    Shahi, Sadhana
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2018, 9 (02): : 824 - 831
  • [26] DEVELOPMENT OF EXTENDED-RELEASE FORMULATION BASED ON THE QUALITY BY DESIGN APPROACH
    Tarapon, Kateryna
    Tryhubchak, Oksana
    ACTA POLONIAE PHARMACEUTICA, 2022, 79 (02): : 231 - 244
  • [27] Development of Tablet Formulation of Amorphous Solid Dispersions Prepared by Hot Melt Extrusion Using Quality by Design Approach
    Anjali Agrawal
    Mayur Dudhedia
    Weibin Deng
    Kevin Shepard
    Li Zhong
    Edward Povilaitis
    Ewa Zimny
    AAPS PharmSciTech, 2016, 17 : 214 - 232
  • [28] Development of Tablet Formulation of Amorphous Solid Dispersions Prepared by Hot Melt Extrusion Using Quality by Design Approach
    Agrawal, Anjali
    Dudhedia, Mayur
    Deng, Weibin
    Shepard, Kevin
    Zhong, Li
    Povilaitis, Edward
    Zimny, Ewa
    AAPS PHARMSCITECH, 2016, 17 (01): : 214 - 232
  • [29] Formulation Development and Characterization of Darunavir and Ritonavir Sustained Release Tablets Using Quality by Design Approach
    Patel, Dhaval
    Patel, Hitesh
    Chaudhary, Hiren
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (53B) : 159 - 172
  • [30] Quality by Design Applied Development of Immediate-Release Rabeprazole Sodium Dry-Coated Tablet
    Lee, Sang-Ho
    Kim, Joo-Eun
    PHARMACEUTICS, 2021, 13 (02) : 1 - 28